Sociodemographic Determinants of COVID-19 Vaccine Hesitancy, Fear of Infection, and Protection Self-Efficacy

Pearl A. McElfish1, Don E. Willis1, Sumit K. Shah1, Keneshia Bryant-Moore2, Martha O. Rojo2, and James P. Selig2

Abstract

Objectives: Arkansas COVID-19 vaccine uptake has been lower than the national average. This study examined associations between sociodemographic factors and COVID-19 vaccine hesitancy, fear of infection, and protection self-efficacy. Methods: Adults either residing, having employment, or receiving health care in Arkansas (n = 754) participated in an online survey between October 30, 2020 and January 16, 2021. Participants were recruited in both rural and urban areas from 6 Arkansas primary care clinics. Survey questions addressed sociodemographic factors, COVID-19 infection fear, protection self-efficacy, and COVID-19 vaccine attitudes. Bivariate and multivariable logistic regression models were used to assess associations between dependent variables and respondents’ sociodemographic characteristics, COVID-19 infection fear, and COVID-19 protection self-efficacy. Results: About 38% of participants reported COVID-19 vaccine hesitancy. Age, sex, race, and education were significantly associated with COVID-19 and general vaccine attitudes. Odds of COVID-19 vaccine hesitancy decreased as age increased (OR = 0.98; P < .01). Women had higher odds of COVID-19 vaccine hesitancy than men (OR = 1.52; P < .05). Respondents with a high school diploma and below and respondents with some college or a technical degree had greater odds of COVID-19 vaccine hesitancy (OR = 2.58; P < .001; and OR = 1.97; P < .01, respectively) compared to respondents with a 4-year college degree. Black/African American respondents had greater odds of COVID-19 vaccine hesitancy compared to White respondents (OR = 3.08; P < .001). No significant difference was observed among rural and urban respondents regarding COVID-19 vaccine hesitancy; however, respondents in rural areas were more likely to report low general vaccine trust compared to those in urban areas (OR = 1.87; P < .01). Respondents reporting no fear (OR = 5.51; P < .001) and very little fear (OR = 1.95; P < .05) of COVID-19 had greater odds of COVID-19 vaccine hesitancy compared to respondents who feared COVID-19 infection to a great extent. Conclusions: COVID-19 vaccine hesitancy and general trust in vaccines differ significantly among age, sex, race, and education. These trust and hesitancy patterns are challenges for achieving population immunity and follow similar patterns of vulnerability to COVID-19. Vaccination programs and interventions must consider these differences in COVID-19 vaccine hesitancy and general vaccine trust to alleviate COVID-19 disparities. Findings make a significant contribution in evaluating vaccine hesitancy among a large, diverse sample from a rural state.

Keywords

COVID-19, vaccine hesitancy, sociodemographic factors, fear, self-efficacy

Introduction

The coronavirus (COVID-19) infection was the third leading cause of death in the United States (US) in 2020,1 and it surpassed the daily mortality rates for heart disease and cancer during the spring of 2020.2 Attaining population immunity through vaccinations is a well-established approach adopted to address infectious outbreaks.3 It has been
estimated that population immunity can be achieved by immunizing approximately 75% to 90% of the population.4 However, surveys conducted before the COVID-19 vaccine was available documented that a large proportion of the global population are hesitant toward COVID-19 immunization.5 The highest COVID-19 vaccine acceptance rates among adults in the general public were found in Ecuador (97.0%), Malaysia (94.3%), Indonesia (93.3%), and China (91.3%), and the lowest rates were found in Kuwait (23.6%), Jordan (28.4%), Italy (53.7), Russia (54.9%), Poland (56.3%), US (56.9%), and France (58.9%).5 Attitudes toward vaccination are generally viewed as existing on a continuum ranging from active demand to complete refusal.6 Populations of racial and ethnic minorities have been differentially affected by COVID-19.7 Variable uptake of vaccines might further worsen the health disparities gap hindering the public health efforts to allocate resources and vaccines appropriately.

Arkansas is a diverse and rural state with 43.84% of the population living in a rural area and 28.00% of the population reporting a race or ethnicity other than non-Hispanic white.8 In an effort to assure access to all populations, COVID-19 vaccines (Pfizer, Moderna, and Johnson & Johnson) have been made widely and freely available in almost all parts of the US, including Arkansas, to all persons who meet age requirements, regardless of insurance status and coverage.10,11 Nevertheless, Arkansas COVID-19 vaccine coverage has been lower than the 2021 US national average.12,13 As of July 2021, the proportion of fully vaccinated individuals in the US was 49.10%, with 57.40% having received at least 1 dose of the vaccine. Conversely, only 35.20% were found to be fully vaccinated in Arkansas, with 43.50% having received at least 1 dose of the vaccine.14,16 Therefore, an online survey approach was used to examine the association between selected sociodemographic factors and COVID-19 vaccine hesitancy among Arkansans. Furthermore, the study examined how fear of COVID-19 infection and self-efficacy to protect against COVID-19 influenced COVID-19 vaccine hesitancy.

**Methods**

Participants were recruited from 6 primary care clinics located throughout rural and urban areas in Arkansas between October 30, 2020 and January 16, 2021. Eligibility criteria included being an adult aged 18 years or older and either residing, having employment, or receiving health care in the state of Arkansas. A recruitment email that included the purpose of the study, the participation eligibility criteria, and the link to voluntarily participate in the survey was sent to 6092 potential respondents. About 876 responses were completed. Out of those, 809 met the eligibility criteria. The final dataset consisted of 754 responses after excluding 21 responses with no data beyond demographic information and 34 duplicate responses.

Before starting the online survey, the potential participants reviewed the study description and consent information. Research Electronic Data Capture (REDCap), a widely used web-based software for capturing survey data, was used to document the written consent and collect responses.17,18 A $20.00 gift card was provided as an incentive to participate in the study. Identifying information was deleted from the downloaded data before conducting the analysis. The Institutional Review Board at the University of Arkansas for Medical Sciences (IRB#261226) approved the study.

The survey included questions about sociodemographic information, vaccine attitudes, and items related to COVID-19. Sociodemographic measures included age, sex, race, and ethnicity, income, education, and urban/rural area as determined by the U.S. Department of Agriculture (USDA) Rural-Urban Commuting Area (RUCA) Codes matched with zip codes. Two key vaccine attitude questions were asked: (1) general vaccine trust and (2) COVID-19 vaccine hesitancy. General vaccine trust was assessed by asking, “Overall how much do you trust vaccines?” Respondents could answer with “not at all,” “very little,” “somewhat,” “to a great extent,” and “completely.” Those who answered “to a great extent” or “completely” were coded as 1 to indicate a high level of trust. The other responses were coded as 0 to indicate lower levels of trust. COVID-19 vaccine hesitancy was measured by asking, “If a vaccine for COVID-19 were available today, what is the likelihood that you would get vaccinated?” Those who selected “don’t know/not sure,” “unlikely,” or “very unlikely” were coded as 1 to indicate hesitancy toward a COVID-19 vaccine. Those who responded that they were “likely” or “very likely” were coded as 0 to indicate they were not hesitant.

Respondents were asked to respond to the statement “I know how to protect myself from COVID-19” to assess COVID-19 self-efficacy. Possible responses included, “not sure at all,” “maybe/not sure,” and “yes, completely sure.” Responses were coded as 1 to indicate uncertainty and 0 to indicate that the respondent was completely sure. Fear of COVID-19 infection was measured by asking respondents to rate their concern about being infected with COVID-19. Respondents could answer by indicating they were concerned “to a great extent,” “somewhat,” “very little,” or “not at all.” These responses were coded from 1 to 4, with higher numbers indicating less fear or more complacency regarding COVID-19 infection.

We tested associations between sociodemographic characteristics, rural/urban residence, fear of COVID-19 infection, and self-efficacy in protecting against COVID-19 with COVID-19 vaccine hesitancy and general trust in vaccines using bivariate analyses (t-tests and chi-square tests) and multivariable logistic regressions. We ran these tests separately for each dependent variable (COVID-19 vaccine hesitancy and general trust in vaccines). Descriptive and
McElfish et al

Bivariate analyses were conducted using Stata/SE 15.1. Mplus 7.3 was used for full-information maximum likelihood (FIML) logistic regression analyses.

Results

Table 1 depicts descriptive statistics for sociodemographics and the independent and dependent variables. The sample is over-representative of women for the state of Arkansas; however, the proportion of those with a 4-year college degree (36.23%) is similar to that of the state population (32.10%). Non-Hispanic white respondents accounted for 70% of the sample, and non-Hispanic black residents accounted for 17%. Over a quarter (27%) of respondents reported a zip code that is considered to be a rural resident by the RUCA codes.

Table 2 depicts bivariate analyses between independent variables and COVID-19 vaccine hesitancy and trust in vaccines in general. There was statistically significant variation in COVID-19 vaccine hesitancy based on age ($t(718)=5.77; P < .001$), sex ($\chi^2(1)=9.88, P < .01$), race/ethnicity ($\chi^2(3)=45.16, P < .001$), income ($\chi^2(3)=18.86, P < .001$), education ($\chi^2(2)=42.36, P < .001$), and fear of infection ($\chi^2(3)=22.96, P < .001$). The average age for

### Table 1. Descriptive Statistics for Phase 2 Sample of Arkansas Adults.

|                          | Frequency | % or $\bar{x}$ | SD     | Range      |
|--------------------------|-----------|----------------|--------|------------|
| **Age**                  | 754       | 47.38          | 16.31  | 18.20-90.60|
| **Sex**                  | 752       |                |        |            |
| Women                    | 531       | 70.42          |        |            |
| Men                      | 221       | 29.31          |        |            |
| **Race/ethnicity**       | 747       |                |        | 1-4        |
| Black/African American   | 128       | 17.14          |        |            |
| White                    | 526       | 70.41          |        |            |
| Other race or multiracial| 61        | 8.17           |        |            |
| Hispanic/Latinx          | 32        | 4.28           |        |            |
| **Income**               | 620       |                |        | 1-4        |
| <$25K                    | 281       | 45.32          |        |            |
| $25K - $50K              | 133       | 21.45          |        |            |
| $50K - $75K              | 72        | 11.61          |        |            |
| $>$75K                   | 134       | 21.61          |        |            |
| **Education**            | 748       |                |        | 1-3        |
| High school or less      | 212       | 28.34          |        |            |
| Some college             | 265       | 35.43          |        |            |
| Four-year college degree | 271       | 36.23          |        |            |
| **Residence**            | 522       |                |        | 0-1        |
| Rural                    | 142       | 27.20          |        |            |
| Urban                    | 380       | 72.80          |        |            |
| **COVID-19 attitudes/feelings** | 717        |                |        | 0-1        |
| COVID-19 self-efficacy   | 717       |                |        |            |
| Maybe/not sure           | 373       | 35.15          |        |            |
| Completely sure          | 709       | 64.85          |        |            |
| **Fear of COVID-19 infection** | 637          |                |        | 1-4        |
| Great extent             | 194       | 30.46          |        |            |
| Somewhat                 | 290       | 45.53          |        |            |
| Very little              | 106       | 16.64          |        |            |
| Not at all               | 47        | 7.38           |        |            |
| **Vaccine confidence**   | 694       |                |        | 0-1        |
| General vaccine trust    | 694       |                |        |            |
| Low trust                | 302       | 43.52          |        |            |
| High trust               | 392       | 56.48          |        |            |
| **Vaccine hesitancy**    | 694       |                |        | 0-1        |
| COVID-19 vaccine hesitancy| 694       |                |        |            |
| Hesitant                 | 279       | 38.75          |        |            |
| Not hesitant             | 441       | 61.25          |        |            |
respondents reporting they were likely or very likely to get the COVID-19 vaccine (50.16) was 7 years higher than the average for those who reported hesitancy (43.09). COVID-19 vaccine hesitancy was higher among women (42.41%) than men (29.86%). COVID-19 vaccine hesitancy was highest among Black/African American respondents (63.03%), followed by Hispanic/Latinx respondents (51.72%), and non-Hispanic other race and multiracial individuals (46.43%)—it was lowest among non-Hispanic White respondents (31.24%). COVID-19 vaccine hesitancy was highest among Black/African American respondents (63.03%), followed by Hispanic/Latinx respondents (51.72%), and non-Hispanic other race and multiracial individuals (46.43%)—it was lowest among non-Hispanic White respondents (31.24%). COVID-19 vaccine hesitancy was highest for those in the lowest income category (45.32%) and steadily declined as income category increased, with the highest income group reporting the lowest hesitancy (24.63%). Respondents with a high school degree or less reported the highest prevalence of COVID-19 vaccine hesitancy (51.01%) across education categories, followed by those with a technical degree or some college (44.31%), and those with a 4-year college degree (23.28%), who reported the lowest prevalence of hesitancy. Respondents who did not fear infection of COVID-19 at all had the highest prevalence of COVID-19 vaccine hesitancy (68.09%). There was no significant difference in COVID-19 vaccine hesitancy by residence or COVID-19 self-efficacy.

There was statistically significant variation in general vaccine trust based on age ($t(692)=-4.51; P<.001$), sex ($\chi^2(1)=9.73, P<.01$), race/ethnicity ($\chi^2(3)=48.24, P<.001$), income ($\chi^2(3)=20.93, P<.001$), and education ($\chi^2(2)=87.11, P<.001$). The average age of those with high trust (50) was over 5 years older than the average age of those with low trust (44). Men had a lower prevalence of low trust (34.47%) than women (47.33%). Non-Hispanic White respondents had the lowest prevalence of low trust (36.14%), followed by Hispanic/Latinx respondents (46.15%), other

| Table 2. Prevalence of COVID-19 Vaccine Hesitancy and General Vaccine Trust among Arkansas Adults. |
|-----------------------------------------------|
| **COVID-19 vaccine hesitancy** | **General vaccine trust** |
| **Hesitant %** | **t-Test or $\chi^2$ | **Low trust %** | **t-Test or $\chi^2$** |
| **(n) or $R$** | **P-value** | **(n) or $R$** | **P-value** |
| Age | 43.09 | $P<.001$ | 44.41 | $P<.001$ |
| Sex | | $P<.01$ | | $P<.01$ |
| Women | 42.41 (215) | | 71.56 (78) | | 36.14 (180) |
| Men | 29.86 (63) | | 36.14 (180) | | 36.14 (180) |
| Race/ethnicity | | $P<.001$ | | $P<.001$ |
| Black/African American | 63.03 (75) | | 36.14 (180) | | 36.14 (180) |
| White | 31.24 (159) | | 36.14 (180) | | 36.14 (180) |
| Other race or multiracial | 46.43 (26) | | 36.14 (180) | | 36.14 (180) |
| Hispanic/Latinx | 51.72 (15) | | 36.14 (180) | | 36.14 (180) |
| Income | | $P<.001$ | | $P<.001$ |
| <$25K | 45.32 (126) | | 49.81 (132) | | 49.81 (132) |
| $25K < $50K | 34.09 (45) | | 44.70 (59) | | 44.70 (59) |
| $50K < $75K | 30.56 (22) | | 34.29 (24) | | 34.29 (24) |
| >$75K | 24.63 (33) | | 27.07 (36) | | 27.07 (36) |
| Education | | $P<.001$ | | $P<.001$ |
| High school or less | 51.01 (101) | | 64.48 (118) | | 64.48 (118) |
| Some college | 44.31 (113) | | 50.61 (125) | | 50.61 (125) |
| Four-year college degree | 23.28 (61) | | 21.92 (57) | | 21.92 (57) |
| Residence | | .98 | | .13 |
| Rural | 34.51 (49) | | 45.19 (61) | | 45.19 (61) |
| Urban | 34.66 (131) | | 37.77 (139) | | 37.77 (139) |
| COVID-19 attitudes/feelings | | .109 | | |
| COVID-19 self-efficacy | | | | |
| Maybe/not sure | 42.40 (106) | | | |
| Completely sure | 36.29 (168) | | | |
| Fear of COVID-19 infection | | $P<.001$ | | |
| Great extent | 34.38 (66) | | | |
| Somewhat | 32.41 (94) | | | |
| Very little | 39.42 (41) | | | |
| Not at all | 68.09 (32) | | | |
racial or multiracial group respondents (53.70%), and Black/African American respondents, who reported the highest prevalence of low trust (71.56%). Low trust was most prevalent among those in lower income categories and those with lower educational attainment.

Table 3 depicts the FIML logistic regression results for vaccine hesitancy specific to the COVID-19 vaccine. The odds of reporting COVID-19 vaccine hesitancy were significantly associated with age, sex, race/ethnicity, education, and fear of infection. The odds of COVID-19 vaccine hesitancy decreased as age increased (OR = 0.98; P < .01). The odds of COVID-19 vaccine hesitancy for women were 1.52 greater than that of men (P < .05). Black/African American respondents had 3.08 times greater odds of vaccine hesitancy compared to White respondents (P < .001). Those with a high school diploma or less education had 2.58 greater odds of COVID-19 vaccine hesitancy than those with a 4-year college degree (P < .001), and those with some college or a technical degree had 1.97 times the odds of vaccine hesitancy compared to those with a 4-year college degree (P < .01). Those who reported very little fear of COVID-19 infection had odds of COVID-19 vaccine hesitancy 1.95 times greater than those who feared it to a great extent (P < .05). Those who felt no fear at all of COVID-19 infection had 5.51 greater odds of COVID-19 vaccine hesitancy compared to those who feared COVID-19 infection to a great extent (P < .001).

Table 4 depicts the FIML logistic regression results for low trust in vaccines in general. The odds of reporting low trust in vaccines decreased as age increased (OR = 0.99; P < .01). Black/African American respondents were 3.29 times more likely to report low trust in vaccines compared to White respondents (P < .001). Respondents who reported multiple races or a race/ethnicity other than Black/African American, White, or Hispanic or Latino, were 1.77 times more likely to report low trust in vaccines compared to White respondents (P < .05). Those who felt no fear at all of COVID-19 infection had 5.51 greater odds of COVID-19 vaccine hesitancy compared to those who feared COVID-19 infection to a great extent (P < .001).

| Table 3. FIML Logistic Regression of COVID-19 Vaccine Hesitancy (N=754). |
|-----------------|-----|------|-----|-----|------|
| Age            | B   | S.E. | OR  | P-value | Sig |
| −0.02          | 0.01| 0.98 | .002| **    |     |
| Sex            |     |   |     |      |     |
| Women          | 0.42| 0.20| 1.52| .033 | *    |
| Men            |     |   |     |      |     |
| Race           |     |   |     |      |     |
| Black/African American | 1.13| 0.24| 3.08| .000| *** |
| White          |     |   |     |      |     |
| Other race or multiracial | 0.57| 0.31| 1.77| .065|   |
| Hispanic/Latinx | 0.78| 0.42| 2.19| .059|   |
| Income         |     |   |     |      |     |
| <$25K          | 0.30| 0.27| 1.35| .272|     |
| $25K-$50K      | 0.16| 0.30| 1.18| .587|     |
| $50K-$75K      | 0.44| 0.35| 1.55| .209|     |
| >$75K          |     |   |     |      |     |
| Education      |     |   |     |      |     |
| High school or less | 0.95| 0.23| 2.58| .000| *** |
| Some college   | 0.68| 0.22| 1.97| .002| ** |
| Four-year college degree |     |   |     |      |     |
| Residence      |     |   |     |      |     |
| Rural          | 0.21| 0.24| 1.23| .388|     |
| Urban          |     |   |     |      |     |
| Fear of COVID-19 infection |     |   |     |      |     |
| Great extent   |     |   |     |      |     |
| Somewhat       | 0.30| 0.22| 1.35| .169|     |
| Very little    | 0.67| 0.28| 1.95| .019| *   |
| Not at all     | 1.71| 0.39| 5.51| .000| *** |
| COVID-19 self-efficacy |     |   |     |      |     |
| Maybe/not sure | 0.28| 0.18| 1.32| .645|     |
| Completely sure |     |   |     |      |     |
| Constant       | −1.53| 0.45| 0.22| .001| ** |

| Table 4. FIML Logistic Regression of Low Trust in Vaccines in General (N=754). |
|-----------------|-----|------|-----|-----|------|
| Age            | B   | S.E. | OR  | P-value | Sig |
| −0.01          | 0.01| 0.99 | .016| *     |     |
| Sex            |     |   |     |      |     |
| Women          | 0.32| 0.20| 1.37| .104|     |
| Men            |     |   |     |      |     |
| Race           |     |   |     |      |     |
| Black/African American | 1.19| 0.25| 3.29| .000| *** |
| White          |     |   |     |      |     |
| Other race or multiracial | 0.68| 0.32| 1.77| .033| *   |
| Hispanic/Latinx | 0.09| 0.45| 1.10| .836|     |
| Income         |     |   |     |      |     |
| <$25K          | 0.24| 0.27| 1.27| .380|     |
| $25K-$50K      | 0.56| 0.29| 1.75| .058|     |
| $50K-$75K      | 0.45| 0.35| 1.56| .204|     |
| >$75K          |     |   |     |      |     |
| Education      |     |   |     |      |     |
| High school or less | 1.86| 0.24| 6.43| .000| *** |
| Some college   | 1.15| 0.22| 3.15| .000| *** |
| Four-year college degree |     |   |     |      |     |
| Residence      |     |   |     |      |     |
| Rural          | 0.63| 0.24| 1.87| .010| ** |
| Urban          |     |   |     |      |     |
| Constant       | −1.49| 0.41| 0.23| .000| *** |

*P < .05, **P < .01, ***P < .001.
in vaccines compared to those with a 4-year college degree \( (P < .001) \). Respondents living in a rural area were 1.87 times more likely to report low trust in vaccines compared to those living in an urban area \( (P < .01) \).

Discussion

This study examined the factors associated with vaccine hesitancy in Arkansas, a rural state with a high proportion of people at-risk for severe COVID-19 if infected. Up to 38.75% of Arkansans demonstrated COVID-19 vaccine hesitancy, compared to the national estimate of vaccine hesitancy closest to the time period (January 2021) of this study (21.60%).\(^1\)\(^3\) Our results reflect a higher proportion of vaccine hesitant people as compared to the other prior recent studies documenting vaccine hesitancy; however, comparisons of hesitancy across studies are challenging due to inconsistent measurement.

We found that hesitancy toward COVID-19 vaccines and trust in vaccines in general vary significantly across sociodemographic groups. COVID-19 and general vaccine attitudes were significantly associated with age, sex, race, and education, with younger respondents and those with lower education and incomes reporting greater hesitancy. These findings were consistent with several other studies that found those who did not intend to be vaccinated were much less likely to be female and much more likely to be Black/African American compared to White.\(^2\)\(^2\)\(^5\) Consistent with prior studies, Black/African American were 3 times as likely to report COVID-19 vaccine hesitancy.\(^4\)\(^5\) These findings were concerning because people with lower incomes and/or lower education levels and communities of color experienced greater COVID-19 disparities in infection, hospitalization, and death.\(^7\) The higher odds COVID-19 vaccine hesitancy among these populations could worsen COVID-19 disparities.

Contemporary literature shows that few studies examined vaccine hesitancy among rural population in the US. Surprisingly, our findings indicated that residing in either a rural or urban area was not associated with COVID-19 hesitancy. This finding was in contrast with prior studies which have shown greater COVID-19 hesitancy among those living in a more ruralized area.\(^26\)\(^27\) However, we did find differences in general vaccine confidence, with rural area residents reporting significantly less trust in vaccines in general compared to those living in urban areas. To our knowledge, this is the first study to document a difference in general vaccine confidence among rural and urban respondents.

Respondents who had less fear of infection by COVID-19 were more likely to report hesitancy toward the COVID-19 vaccination. Respondents who reported they did not fear contracting COVID-19 infection had 5 times greater odds of vaccine hesitancy compared to respondents who feared infection to a great extent. This finding was consistent with general vaccine hesitancy studies\(^28\) and is among the first studies to document fear as a predictor of COVID-19 vaccine hesitancy.

Limitations

This study does have some limitations. Because the data are cross-sectional, we were unable to determine causality or assess trends in COVID-19 vaccine hesitancy across time. The study recruited participants who were patients at 6 clinics and may not represent the responses of participants without a primary care provider or who do not have e-mail addresses. Despite the limitations, this study makes a significant contribution in evaluating vaccine hesitancy among a large and diverse sample from a rural state.

Conclusions

Hesitancy toward the COVID-19 vaccine and general trust in vaccines differ significantly among age, sex, race, and education, with younger respondents and those with lower education and incomes reporting greater hesitancy. These patterns of hesitancy and trust are worrisome because they are a challenge for achieving population immunity and because they follow similar patterns of vulnerability to COVID-19 itself. Vaccination programs and interventions which do not consider these differences in COVID-19 vaccine hesitancy and general vaccine trust may exacerbate rather than alleviate existing COVID-19 disparities.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research described was supported by the Translational Research Institute (TRI) (grant number UL1 TR003107) through the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) and through an award from NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities (grant number 1OT2HL161580—01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Ethical Approval

The Institutional Review Board at the University of Arkansas for Medical Sciences (IRB#261226) approved the study.
References

1. Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. *JAMA*. 2021;325(18):1829-1830. doi:10.1001/jama.2021.5469
2. Woolf SH, Chapman DA, Lee JH. COVID-19 as the leading cause of death in the United States. *JAMA*. 2021;325(2):123-124. doi:10.1001/jama.2020.24865
3. Mallory ML, Lindesmith LC, Baric RS. Vaccination-induced herd immunity: successes and challenges. *J Allergy Clin Immunol*. 2018;142(1):64-66. doi:10.1016/j.jaci.2018.05.007
4. Anderson R, Vegvari C, Truscott J, Collyer B. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. *Lancet*. 2020;396(10263):1614-1616. doi:10.1016/S0140-6736(20)32318-7
5. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. *Vaccines*. 2021;9(2):160. doi:10.3390/vaccines9020160
6. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger JA. Vaccine hesitancy: an overview. *Hum Vaccin Immunother*. 2013;9(8):1763-1773.
7. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No populations left behind: vaccine hesitability and equitable diffusion of effective COVID-19 vaccines. *J Gen Intern Med*. 2021;36(7):2130-2133. doi:10.1007/s11606-021-06698-5
8. United States Census Bureau. ACS Demographic And Housing Estimates. 2019. Accessed June 3, 2021. https://data.census.gov/cedsci/table?q=race%20and%20ethnicity&g=0400000US05&tid=ACSPP1Y2019.DP0
9. United States Census Bureau. Rural and urban (Arkansas). 2010. Accessed June 3, 2021. https://data.census.gov/cedsci/table?q=urban20area&g=0400000US05&tid=DECENNIAL LCD1132010.P2
10. United States Department of Health and Human Services. COVID-19 vaccine coverage regardless of insurance status. United States Department of Health and Human Services, Assistant Secretary for Public Affairs. 2021. Accessed May 31, 2021. https://www.hhs.gov/coronavirus/care-act-provider-relief-fund/for-patients/index.html
11. Arkansas Department of Health. COVID-19 vaccination locations. Arkansas Department of Health. 2021. Accessed May 31, 2021. https://www.healthy.arkansas.gov/programs-services/topics/covid-19-map-of-1-a-pharmacy-locations
12. Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. Centers for Disease Control and Prevention. 2021. Accessed May 4, 2021. https://covid.cdc.gov/covid-data-tracker/#/vaccinations
13. Anderson L, File T, Marshall J, McElrath K, Scherer Z. New tool tracks vaccination and vaccine hesitancy rates across geographies, population groups. United States Census Bureau. 2021. Updated April 14, 2021. Accessed May 31, 2021. https://www.census.gov/library/stories/2021/04/how-do-covid-19-vaccination-and-vaccine-hesitancy-rates-vary-over-time.html?utm_campaign=20210526mdsvs1ecdtanl&utm_medium=email&utm_source=govdelivery
14. Centers for Disease Control and Prevention. COVID data tracker. Centers for Disease Control and Prevention. 2020. Updated March 28, 2020. Accessed June 27, 2021. https://covid.cdc.gov/covid-data-tracker
15. Arkansas Department of Health. COVID-19. Arkansas Department of Health. 2021. Accessed June 27, 2021. https://www.healthy.arkansas.gov/programs-services/topics/novel-coronavirus
16. United States Department of Health and Human Services. COVID-19 state profile report – combined set. 2021. Accessed July 26, 2021. https://healthdata.gov/Community/COVID-19-State-Profile-Report-Combined-Set/5mth-2h7d
17. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
18. Harris P, Taylor R, Thiellke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
19. Stata Statistical Software: Release 15. StataCorp LLC; 2017.
20. Muthén LK, Muthén BO. *Mplus User’s Guide*. 8th ed. Muthén & Muthén; 1998-2017.
21. United States Census Bureau. QuickFacts. 2020. Accessed July 28, 2021. https://www.census.gov/quickfacts/fact/table/US/RH1125219
22. Latkin C, Dayton LA, Yi G, et al. COVID-19 vaccine intentions in the United States, a social-ecological framework. *Vaccine*. 2021;39(16):2288-2294. doi:10.1016/j.vaccine.2021.02.058
23. Funk C, Tyson A, Kennedy B, Johnson C, Thigpen CL, Spencer A. Intent to get a COVID-19 vaccine rises to 60% as confidence in research and development process increases. 2020. Accessed May 31, 2021. https://www.pewresearch.org/science/2020/12/03/intent-to-get-a-covid-19-vaccine-rises-to-60-as-confidence-in-research-and-development-process-increases/
24. Meier BP, Dillard AJ, Lappas CM. Predictors of the intention to receive a SARS-CoV-2 vaccine. *J Public Health (Oxf)*. Published online March 3, 2021. doi:10.1093/pubmed/fdad013
25. Doherty IA, Pilkington M, Fiscus M, Hohmeier KC, Chisholm-Burns M. Factors influencing likelihood of COVID-19 vaccination: a survey of Tennessee adults. *Am J Health Syst Pharm*. 2021;78(10):879-889. doi:10.1093/ajhp/zxab099
26. Galton J, McKnight M, Fiscus M, Hohmeier KC, Chisholm-Burns M. Factors influencing likelihood of COVID-19 vaccination: a survey of Tennessee adults. *Am J Health Syst Pharm*. 2021;78(10):879-889. doi:10.1093/ajhp/zxab099
27. Salmon DA, Dudley MZ, Brewer J, et al. COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization. *Vaccine*. 2021;39(19):2698-2711. doi:10.1016/j.vaccine.2021.03.034
28. Larson HJ. Vaccine trust and the limits of information. *Science*. 2016;353(6305):1207-1208. doi:10.1126/science.aah6190

ORCID iD

Pearl A. McElfish https://orcid.org/0000-0002-4033-6241